Liberty® Robotic System Achieves 100% Navigation Success in Trial
Microbot Medical presented positive data from its ACCESS-PVI pivotal trial for the LIBERTY® Endovascular Robotic System at the Society...
Grace Therapeutics and FDA Align on GTX-104 NDA Submission
Grace Therapeutics, a late-stage biopharmaceutical company, announced positive feedback from the FDA regarding its planned New Drug Application (NDA)...
Context Therapeutics Doses First Patient in Phase 1 Trial of CT-95
Context Therapeutics has dosed the first patient in a Phase 1 clinical trial for CT-95, a bispecific antibody targeting...
Bemnifosbuvir and Ruzasvir in Phase 3 HCV Study
Atea Pharmaceuticals has initiated its Phase 3 C-BEYOND trial, evaluating the bemnifosbuvir and ruzasvir regimen for chronic hepatitis C...
KSQ Doses First Patient in CRISPR TIL Therapy Trial
KSQ Therapeutics has dosed the first patient in a Phase 1/2 clinical trial for KSQ-004EX, a CRISPR-engineered tumor-infiltrating lymphocyte...
Digital Lung Simulations in Pulmonary Fibrosis Drug Development
Ebenbuild’s Twinhale technology, a software for creating digital lung twins, was used in a preclinical study on idiopathic pulmonary...
Inna-051 Antiviral Phase 2 Study: Respiratory Disease Breakthrough
ENA Respiratory is partnering with the University of Maryland’s Center for Vaccine and Global Development (CVDGH) to conduct a...
Assembly Biosciences Presents New Data on Herpes Simplex Virus Candidate at ESCMID
Assembly Biosciences presented data at the 2025 ESCMID Congress on ABI-5366, a novel, long-acting helicase-primase inhibitor candidate for recurrent...
MN-166 ALS Trial: First Patient Enrolled in NIH-Funded EAP
MediciNova has enrolled the first patient in a National Institutes of Health (NIH)-funded Expanded Access Program (EAP) to evaluate...
Annexon at AAN: GBS Data & New Education Campaign
Annexon, Inc. presented Phase 3 trial data for tanruprubart (formerly ANX005), a C1q-blocking monoclonal antibody, at the 2025 AAN...